Jazz Pharmaceuticals (JAZZ) Receives a Buy from Barclays
In a report released today, Etzer Darout from Barclays maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $224.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Darout is a 5-star analyst with an average return of 25.7% and a 56.33% success rate. Darout covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals, CytomX Therapeutics, and Incyte.
In addition to Barclays, Jazz Pharmaceuticals also received a Buy from TipRanks – Google’s Google Biotechnology in a report issued yesterday. However, on the same day, TipRanks – Anthropic reiterated a Hold rating on Jazz Pharmaceuticals (NASDAQ: JAZZ).
Based on Jazz Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.2 billion and a net profit of $203.45 million. In comparison, last year the company earned a revenue of $1.09 billion and had a net profit of $191.12 million
Based on the recent corporate insider activity of 82 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JAZZ in relation to earlier this year. Most recently, in December 2025, Mary Elizabeth Henderson, the SVP Tech. Op of JAZZ sold 2,238.00 shares for a total of $379,363.38.
Read More on JAZZ:
Disclaimer & DisclosureReport an Issue
- Jazz Pharmaceuticals initiated with an Overweight at Barclays
- Jazz Pharmaceuticals price target raised to $226 from $225 at Morgan Stanley
- Jazz Pharmaceuticals price target raised to $255 from $210 at Deutsche Bank
- Jazz Pharmaceuticals price target raised to $275 from $263 at BofA
- Jazz Pharmaceuticals price target raised to $250 from $235 at Wells Fargo
